“CemiplimAb-Rwlc Survivorship and Epidemiology (CASE): A Prospective Study of the Safety and Efficacy of Cemiplimab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC) in a Real-World Setting”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s174. https://doi.org/10.25251/skin.7.supp.174.